Table 1
| Disease Site |
Study | Study Name | Open Date | Number of Active Institutions |
Number of Current IRBs |
|---|---|---|---|---|---|
| BREAST | S1416 | Brst, TNBC/BRCA, Cis+/- ABT-888 | 07-JUL-16 | 259 | 114 |
| S1418 | Breast, Adj, TNBC, MK-3475 (Pembrolizumab) | 15-NOV-16 | 477 | 210 | |
| S1706 | Breast, Inflammatory, RT +/- Olaparib | 12-SEP-18 | 0 | 66 | |
| A011106 | Breast, Neoadj, ALTERNATE study | 15-FEB-14 | 279 | 128 | |
| A011401 | Breast, adj, Stage II/III HER2-, weight loss | 29-AUG-16 | 489 | 251 | |
| A011502 | Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo | 08-DEC-16 | 0 | 207 | |
| A221405 | Breast, ET interruption, Pregnancy Outcomes | 15-OCT-15 | 0 | 51 | |
| B51 | Breast, Regional Nodal XRT | 22-AUG-13 | 284 | 157 | |
| B55 | Brst, Adj Olaparib for BRCA,TNBC | 03-JUL-14 | 326 | 141 | |
| EA1131 | Brst, TNBC, Post-op Chemo vs Obs | 20-AUG-14 | 258 | 122 | |
| EA1151 | Brst, Tomosynthesis Mammographic Screening | 06-JUL-17 | 0 | 76 | |
| NRGBR002 | Brst, OMBC, II-III, SoC +/- SBRT and/or SA | 24-DEC-14 | 0 | 114 | |
| NRGBR003 | Brst,Adj,TNBC,AC -> WP +/- Carbo | 22-JAN-15 | 318 | 168 | |
| NRGBR005 | Br, Stg II&IIIA, Post NAdj Chemo Br Conserv | 13-APR-17 | 0 | 81 | |
| CCD | S1703 | Met Breast, STM-monitoring v Usual Care | 16-JUL-18 | 0 | 76 |
| A191402C | PROS, Testing Decision Aids for Minority Men | 14-JUL-17 | 0 | 11 | |
| ACCL16N1 | Guideline Consistent Treatment AYA ALL | 18-DEC-17 | 0 | 49 | |
| EAQ162CD | CCD, Financial Burden, Colon & Rectal Cancer | 17-MAY-18 | 0 | 67 | |
| ERLYTX | S1609 | Rare Tumor, Comb Nivo/Ipi | 13-JAN-17 | 323 | 152 |
| A071401 | Prog Meningiomas,SMO/AKT/NF2 Inhib | 06-AUG-15 | 230 | 91 | |
| ARST1321 | NonRhabdo STS,Pazopanib (PAZNTIS) | 16-MAY-14 | 102 | 64 | |
| EAY131 | MATCH | 12-AUG-15 | 382 | 210 | |
| GI | S1613 | mCRC, Adv/Met, TP vs CETIRI | 09-OCT-17 | 0 | 115 |
| S1815 | Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel | 03-DEC-18 | 0 | 84 | |
| A021502 | Colon, Stg III, Chemo +/- Atezol, ATOMIC | 12-SEP-17 | 0 | 165 | |
| A021602 | PANC, Adv PNET Blinded Cabozantinib v Placebo | 18-JUL-18 | 0 | 1 | |
| EA2142 | GI NEC, Adv G3, EP vs TMZ + CAP | 06-NOV-15 | 190 | 78 | |
| EA2161 | PANC, Adv Rapalog Resistant PNETs, MLN0128 | 01-FEB-17 | 0 | 21 | |
| EA2165 | Anal, Stg II-III, Nivolumab after CMT | 13-APR-18 | 0 | 50 | |
| NRGGI004 | Colorectal, Stg IV, dMMR Immuno-Therapy | 07-NOV-17 | 0 | 124 | |
| GU | S1500 | pRCC,Adv, Sunitinib vs MET inhib | 05-APR-16 | 214 | 87 |
| S1602 | Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG | 07-FEB-17 | 177 | 77 | |
| S1605 | Blad, BCG-Unresponsive NMIBC, Atezolizumab | 07-FEB-17 | 207 | 93 | |
| S1802 | Pros, Stg IV, SST +/- Surg/RT to Primary Tum | 17-SEP-18 | 0 | 101 | |
| S1806 | Blad, MIBC, ChemoRT +/- Atezolizumab | 19-APR-19 | 0 | 60 | |
| A031102 | GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) | 01-JUL-15 | 60 | 37 | |
| A031501 | Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs | 21-SEP-17 | 0 | 129 | |
| A031701 | Bladder, ddGC for MIBC with DDR Tumor Alt | 01-AUG-18 | 0 | 43 | |
| EA8143 | RCC, HR, Surg +/- Nivolumab (PROSPER) | 02-FEB-17 | 0 | 135 | |
| EA8153 | Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) | 08-FEB-18 | 0 | 94 | |
| EA8171 | PROS, newly diagnosed, mpMRI for pre-op stagi | 09-JUL-18 | 0 | 32 | |
| NRGGU002 | Pros, RT + ADT After RP +/- Adj Docetaxel | 30-DEC-16 | 0 | 110 | |
| NRGGU005 | PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT | 16-NOV-17 | 0 | 26 | |
| NRGGU006 | PROS, post-RP PSA, SRT +/- ADT w/Apalutamide | 27-APR-18 | 0 | 18 | |
| R0924 | Pros, NADT+WPRT vs. NADT+P&SV RT | 07-JUL-11 | 0 | 114 | |
| LEUK | S1712 | CML, Chronic Phase, TKI +/- Ruxolitinib | 20-JUL-18 | 0 | 62 |
| A041501 | B-Cell ALL, Frontline Tx +/- Intuzumab Ozo | 01-JUN-17 | 0 | 56 | |
| A041701 | AML, Age 60+, Conv Chemo +/- Uproleselan | 16-JAN-19 | 0 | 2 | |
| A041702 | CLL, Stg I-IV, IO with IM versus IVO | 04-JAN-19 | 0 | 26 | |
| E1910 | BCR-ABL-neg, B ALL, Blinatumomab | 23-DEC-13 | 199 | 97 | |
| E2906 | AML, Age 60+, Clo vs Dauno+Cy | 24-FEB-11 | 91 | 40 | |
| EA9161 | CLL, untreated, IOV vs IO in younger pts | 03-JAN-19 | 0 | 67 | |
| LUNG | S1619 | Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC | 03-NOV-17 | 0 | 31 |
| S1701 | Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac | 09-AUG-18 | 0 | 31 | |
| S1800A | Non-Match: Ramu + Pembro vs SoC | 17-MAY-19 | 0 | 52 | |
| S1900A | LOH and/or BRCA: Rucaparib | 28-JAN-19 | 0 | 93 | |
| A081105 | ALCHEMIST1, EGFR mut, Erlotinib | 02-JAN-14 | 0 | 278 | |
| A151216 | ALCHEMIST0 - screening | 06-FEB-14 | 499 | 280 | |
| C30610 | SCLC, Thoracic RT | 21-MAR-08 | 156 | 85 | |
| E4512 | ALCHEMIST2, ALK mut, Crizotinib | 18-AUG-14 | 383 | 219 | |
| EA5142 | ALCHEMIST3, Non-match, Nivolumab | 16-MAY-16 | 467 | 270 | |
| EA5163 | NSCLC, Immunotherapy +/- 2nd line therapy | 28-FEB-19 | 0 | 11 | |
| LUNGMAP | NSCLC, Adv, Master | 28-JAN-19 | 0 | 154 | |
| NRGCC003 | SCLC, PCI or HA-PCI | 07-DEC-15 | 240 | 123 | |
| LYMPH | S1608 | FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | 10-AUG-17 | 0 | 94 |
| A051301 | ABC DLBCL, Auto HCT and Ibrutinib/Placebo | 15-JUL-16 | 163 | 66 | |
| E4412 | HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin | 24-JAN-14 | 0 | 1 | |
| EA4151 | Lymph, AHCT +/-Ritux, MRD Neg | 29-AUG-17 | 0 | 61 | |
| MELAN | S1512 | Melan, Adv, Desmoplastic, MK-3475 (pembro) | 20-OCT-16 | 111 | 50 |
| S1607 | MELAN, Adv, T-VEC, MK-3475 | 02-OCT-17 | 0 | 26 | |
| S1616 | MELAN, Adv, Ipilimumab ± Nivolumab | 17-JUL-17 | 0 | 91 | |
| S1801 | Melan, Adv, Adj vs Neoadj Pembrolizumab | 06-DEC-18 | 0 | 102 | |
| EA6134 | Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T | 15-DEC-15 | 362 | 144 | |
| EA6141 | Melan, Avd, Nivolumab+Ipi ± Sargmostim | 01-MAR-16 | 221 | 93 | |
| EA6174 | Merkel, Adjuvant Pembrolizumab vs Observation | 23-JUL-18 | 0 | 24 | |
| MMYEL | S1702 | AL Amyloidosis, Relapsed, Isatuximab | 08-MAR-18 | 0 | 58 |
| E1A11 | MM, frontline, BLD vs CLD | 22-NOV-13 | 299 | 123 | |
| OTHER | A091401 | Sarc, | 18-JUN-15 | 180 | 71 |
| EA3132 | HN SCC, Stg III-IV , Adj RT +/- Cisp | 29-MAR-16 | 0 | 68 | |
| EAF151 | Brain, GBM, Bev, Blood Volume | 14-APR-17 | 0 | 43 | |
| EAQ152 | Communication & education in tumor profiling | 26-SEP-16 | 183 | 82 | |
| G0263 | Cerv, Stg I/IIA, adjv RT vs chemoRT | 12-APR-10 | 0 | 47 | |
| N0577 | BRN, Glio,Tem vs Tem+RT vsRT+PVC | 22-SEP-09 | 163 | 75 | |
| NRGBN001 | HN, novel vs. std chemoradiation + chemo | 28-AUG-15 | 0 | 73 | |
| NRGGY005 | OVAR, Cedir vs Olaparib vs C+O vs Std of Care | 06-FEB-16 | 336 | 153 | |
| NRGGY009 | Ovar, PLD/Atexo vs PLD/Atezo/Bev vs PLD/Bev | 12-MAY-17 | 0 | 129 | |
| NRGGY012 | End, Recurrent/Met, Ola vs Cedir vs Ola+Cedir | 04-SEP-18 | 0 | 9 | |
| NRGHN001 | Nasopharyngeal , Indiviual Tx EBV | 21-APR-14 | 148 | 65 | |
| R0724 | Cervical, Chem+RT +/- Adj. Chemo | 15-JAN-14 | 204 | 90 | |
| R1216 | HN, Adv,Cis vs Dtx vs Dtx+Cetux | 18-MAR-13 | 205 | 84 | |
| PREV | A211601 | Breast, Stg II-III, Aspirin | 01-AUG-18 | 0 | 13 |
| NHLBIMDS | LEUK, National MDS Study | 05-APR-16 | 215 | 81 | |
| SURV | S1501 | Surv, Breast Stg IV, Card Tox w/ Carvedilol | 15-SEP-17 | 0 | 92 |
| E1Q11 | EROS: Reproductive Health in Cancer Survivors | 30-SEP-15 | 0 | 42 | |
| EA9131 | Leuk, Strategy to decrease early APL deaths | 16-AUG-17 | 0 | 29 | |
| SXQOL | S1600 | Bladder,Radical Cystectomy Outcomes Nutrition | 21-FEB-19 | 0 | 24 |
| S1614 | HBV in Ca Pts, TAF vs SOC | 21-FEB-19 | 0 | 19 | |
| S1714 | CIPN Risk Prediction Cohort Study, Taxanes | 01-MAR-19 | 0 | 28 | |
| A221504 | NSCL, Advanced, placebo vs naloxegol | 13-OCT-17 | 0 | 72 | |
| A221505 | Brst, Hypofractionated Post Mast Rad | 01-FEB-18 | 0 | 98 | |